This study aimed to characterize changes in estimated past-year lysergic acid diethylamide (LSD) use among sexual minorities in the United States using nationally representative data and to compare correlates of LSD use between lesbian, gay, and bisexual individuals (LGB) and heterosexual individuals.
Method:
Using National Survey on Drug Use and Health data on adults from 2015 to 2019, we investigated correlates of past-year LSD use among LGB individuals compared with heterosexual individuals and changes in the prevalence of past-year LSD use during that period. Correlates were identified with weighted logistic regression.
Results:
LGB individuals constituted approximately 5% of the sample. From 2015 to 2019 estimated prevalence of past-year LSD use rose 43% in heterosexual individuals, 58% in bisexual individuals, and 106% in lesbian/gay individuals. The relative risk for LSD use ranged from 3.3 to 4.4 times higher for LGB individuals compared with heterosexual individuals during the study period, depending on the year. Interaction analysis found that living in poverty, being divorced versus married, living in a small metropolitan area versus a non-metropolitan area, and past-year suicide attempt were unique correlates of past-year LSD use for heterosexual individuals compared with LGB individuals.
Conclusions:
Sexual minorities are at increased risk of past-year LSD use compared with heterosexual individuals. There were notable increases in past-year LSD use from 2015 to 2019 among heterosexual, bisexual, and lesbian/gay individuals, with a marked increase in the latter group. These findings highlight the possible need for targeted LSD harm reduction strategies based on sexual identity and more inclusive research on psychedelic use.
ReiffCM, RichmanEE, NemeroffCB, et al.; the Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research. Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry, 2020; 177(5):391–410; doi: 10.1176/appi.ajp.2019.19010035
2.
BarnettBS, WeleffJ. Psychedelics in the treatment of substance use disorders. Psychiatr Ann, 2022; 52(9):365–370; doi: 10.3928/00485713-20220804-01
3.
SandisonRA, WhitelawJD. Further studies in the therapeutic value of lysergic acid diethylamide in mental illness. J Ment Sci, 1957; 103(431):332–343; doi: 10.1192/bjp.103.431.332
4.
BallJR, ArmstrongJJ. The use of L.S.D. 25 (D-lysergic acid diethylamide) in the treatment of the sexual perversions. Can Psychiatr Assoc J, 1961; 6:231–235; doi: 10.1177/070674376100600407
5.
SípováI. [The therapy with lsd in homosexual males and transsexual females (author’s transl)]. Cas Lek Cesk, 1974; 113(48):1491–1493.
6.
MartinAJ. The treatment of twelve male homosexuals with ‘L.S.D.’ (followed by a Detailed account of one of them who was a psychopathic personality). Psychother Psychosom, 1962; 10(5):394–402; doi: 10.1159/000285648
7.
HanshawBD, FusunyanM, AndersonCTM, et al.Psychedelic-assisted therapy among sexual and gender minority communities. Nat Mental Health, 2024; 2(6):636–644; doi: 10.1038/s44220-024-00252-y
8.
CarlisleNA, DourronHM, MacCarthyS, et al.Exploring the unique therapeutic potential of psychedelics to reduce chronic shame among sexual and gender minority adults. Psychedelic Med (New Rochelle), 2023; 1(4):210–217; doi: 10.1089/psymed.2022.0018
9.
MarshalMP, FriedmanMS, StallR, et al.Sexual orientation and adolescent substance use: A meta-analysis and methodological review. Addiction, 2008; 103(4):546–556; doi: 10.1111/j.1360-0443.2008.02149.x
10.
JunH-J, Webb-MorganM, FelnerJK, et al.Sexual orientation and gender identity disparities in substance use disorders during young adulthood in a United States longitudinal cohort. Drug Alcohol Depend, 2019; 205:107619; doi: 10.1016/j.drugalcdep.2019.107619
11.
KruegerEA, FishJN, UpchurchDM. Sexual orientation disparities in substance use: Investigating social stress mechanisms in a national sample. Am J Prev Med, 2020; 58(1):59–68; doi: 10.1016/j.amepre.2019.08.034
12.
BrooksBD, JobSA, KaniukaAR, et al.Healthcare discrimination and treatment adherence among sexual and gender minority individuals living with chronic illness: The mediating effects of anticipated discrimination and depressive symptoms. Psychol Health, 2025; 40(2):304–320; doi: 10.1080/08870446.2023.2220008
13.
FingerhutAW, MartosAJ, ChoiSK, et al.Healthcare stereotype threat and health outcomes among LGB individuals. Ann Behav Med, 2022; 56(6):562–572; doi: 10.1093/abm/kaab060
14.
ApodacaC, Casanova-PerezR, BascomE, et al.Maybe they had a bad day: How LGBTQ and BIPOC patients react to bias in healthcare and struggle to speak out. J Am Med Inform Assoc, 2022; 29(12):2075–2082; doi: 10.1093/jamia/ocac142
15.
Anonymous. Leading Health Indicators for Healthy People 2020: Letter Report. National Academy of Sciences: Washington (DC); 2020.; doi: 10.17226/13088
16.
LeeJ, ParkerMA. Psychedelic use by sexual minority adults in the united states, 2022. Am J Prev Med, 2024; 67(5):770–772; doi: 10.1016/j.amepre.2024.06.006
17.
DharmaC, LiuE, GraceD, et al.Factors associated with the use of psychedelics, ketamine and MDMA among sexual and gender minority youths in Canada: A machine learning analysis. J Epidemiol Community Health, 2024; 78(4):248–254; doi: 10.1136/jech-2023-220748
18.
RemyLS, SchererJ, GuimarãesL, et al.Anxiety and depression symptoms in Brazilian sexual minority ecstasy and LSD users. Trends Psychiatry Psychother, 2017; 39(4):239–246; doi: 10.1590/2237-6089-2016-0081
19.
YockeyRA, VidourekRA, KingKA. Trends in LSD use among US adults: 2015–2018. Drug Alcohol Depend, 2020; 212:108071; doi: 10.1016/j.drugalcdep.2020.108071
20.
WeleffJ, AnandA, DeweyEN, et al.LSD use in the United States: Examining user demographics and their evolution from 2015–2019. Jps, 2024; doi: 10.1556/2054.2024.00309
21.
BarnettBS, AnandA, DeweyEN, et al.Perceived risk of trying lysergic acid diethylamide in the united states from 2015 to 2019: Are americans assessing lysergic acid diethylamide’s risk profile more favorably? Psychedelic Medicine, 2024; 2(2):74–86; doi: 10.1089/psymed.2023.0027
22.
Center for Behavioral Health Statistics and Quality. 2019 National Survey on Drug Use and Health (NSDUH) Methodological Resource Book, Section 13: Statistical Inference Report. 2021.
23.
Center for Behavioral Health Statistics and Quality. 2019 NATIONAL SURVEY ON DRUG USE AND HEALTH (NSDUH): FINAL CAI SPECIFICATIONS FOR PROGRAMMING (ENGLISH VERSION). Substance Abuse and Mental Health Services Administration: Rockville, MD; 2018.
24.
Substance Abuse and Mental Health Services Administration. Lesbian, Gay, and Bisexual Behavioral Health: Results from the 2021 and 2022 National Surveys on Drug Use and Health. 2023.
25.
HosmerD, LemeshowS. Applied Logistic Regression. Wiley: New York, NY; 2000.
26.
MustanskiB, Van WagenenA, BirkettM, et al.Identifying sexual orientation health disparities in adolescents: Analysis of pooled data from the Youth Risk Behavior Survey, 2005 and 2007. Am J Public Health, 2014; 104(2):211–217; doi: 10.2105/AJPH.2013.301748
27.
SeilKS, DesaiMM, SmithMV. Sexual orientation, adult connectedness, substance use, and mental health outcomes among adolescents: Findings from the 2009 New York City Youth Risk Behavior Survey. Am J Public Health, 2014; 104(10):1950–1956; doi: 10.2105/AJPH.2014.302050
28.
McCabeSE, HughesTL, BostwickWB, et al.Sexual orientation, substance use behaviors and substance dependence in the United States. Addiction, 2009; 104(8):1333–1345; doi: 10.1111/j.1360-0443.2009.02596.x
29.
CorlissHL, RosarioM, WypijD, et al.Sexual orientation and drug use in a longitudinal cohort study of U.S. adolescents. Addict Behav, 2010; 35(5):517–521; doi: 10.1016/j.addbeh.2009.12.019
30.
FlentjeA, HeckNC, BrennanJM, et al.The relationship between minority stress and biological outcomes: A systematic review. J Behav Med, 2020; 43(5):673–694; doi: 10.1007/s10865-019-00120-6
31.
LeeJ, Evans-PolceRJ, AhlquistJ, et al.Polysubstance use by sexual identity among US adults, 2021. Prev Med, 2023; 177:107729; doi: 10.1016/j.ypmed.2023.107729
32.
Substance Abuse and Mental Health Services Administration. 2019 National Survey on Drug Use and Health Public Use File Codebook. Substance Abuse and Mental Health Services Administration: Rockville, MD; 2020.
33.
KesslerRC, BarkerPR, ColpeLJ, et al.Screening for serious mental illness in the general population. Arch Gen Psychiatry, 2003; 60(2):184–189; doi: 10.1001/archpsyc.60.2.184
34.
LeeY-H, ChangY-C, ShelleyM, et al.Sexual minority identifiers and their perception of illicit drug use risks in the US: Results from a National Survey. J Psychiatr Res, 2024; 175:183–191; doi: 10.1016/j.jpsychires.2024.05.010
35.
SchulerMS, Evans-PolceRJ. Perceived Substance Use Risks Among Never Users: Sexual Identity Differences in a Sample of U.S. Young Adults. Am J Prev Med, 2022; 63(6):987–996; doi: 10.1016/j.amepre.2022.07.003
36.
HillAO, AmosN, LyonsA, et al.Illicit drug use among lesbian, gay, bisexual, pansexual, trans and gender diverse, queer and asexual young people in Australia: Intersections and associated outcomes. Drug Alcohol Rev, 2023; 42(3):714–728; doi: 10.1111/dar.13585
37.
BarnettBS, AnandA, DeweyEN, et al.Perceived Availability of Lysergic Acid Diethylamide in the United States from 2015 to 2019. Psychedelic Medicine n.d, 2025; 0(0):null; doi: 10.1089/psymed.2024.0045
38.
BartlettA, ChristC, MartinsB, et al.The library is open: A scoping review on queer representation in psychedelic research. Front Public Health, 2024; 12:1472559; doi: 10.3389/fpubh.2024.1472559
39.
LancelottaR, DellaCrosseM, QuinnD, et al.Exploring Self-Reported Effects of Naturalistic Psychedelic Use Among Gender and Sexual Minorities: A Quantitative Survey Study. J Psychoactive Drugs, 2025:1–14; doi: 10.1080/02791072.2025.2520224
40.
RaisonCL, SanacoraG, WoolleyJ, et al.Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 2023; 330(9):843–853; doi: 10.1001/jama.2023.14530
41.
GoodwinGM, AaronsonST, AlvarezO, et al.Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med, 2022; 387(18):1637–1648; doi: 10.1056/NEJMoa2206443
42.
RobisonR, BarrowR, ConantC, et al.Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial. JAMA, 2025; 334(15):1358–1372; doi: 10.1001/jama.2025.13481
43.
HartogsohnI. Constructing drug effects: A history of set and setting. Drug Sci Policy Law, 2017; 3:2050324516683325; doi: 10.1177/2050324516683325
44.
HaftSL, DowneyAE, Raymond-FleschM, et al.A systematic review of participant diversity in psychedelic-assisted psychotherapy trials. Psychiatry Res, 2025; 345:116359; doi: 10.1016/j.psychres.2025.116359
45.
HinkleJT, GraziosiM, NayakSM, et al.Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis. JAMA Psychiatry, 2024; 81(12):1225–1235; doi: 10.1001/jamapsychiatry.2024.2546
46.
KopraEI, FerrisJA, RuckerJJ, et al.Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD). J Psychopharmacol, 2022; 36(8):956–964; doi: 10.1177/02698811221099650
47.
OpitzE. Die klinische Therapie seelischer Störungen mit Lysergsäure. Psychiatrie, Neurologie Und Medizinische Psychologie, 1963; 15(9):366–372.
48.
LakeCR, StirbaAL, KinnemanREJ, et al.Mania associated with LSD ingestion. Am J Psychiatry, 1981; 138(11):1508–1509; doi: 10.1176/ajp.138.11.1508
49.
CohenS, DitmanKS. Prolonged adverse reactions to lysergic acid diethylamide. Arch Gen Psychiatry, 1963; 8:475–480; doi: 10.1001/archpsyc.1963.01720110051006
50.
CohenS. LSD: The varieties of psychotic experience. J Psychoactive Drugs, 1985; 17(4):291–296; doi: 10.1080/02791072.1985.10524333
51.
Le DaréB, GicquelT, BaertA, et al.Self-inflicted neck wounds under influence of lysergic acid diethylamide: A case report and literature review. Medicine (Baltimore), 2020; 99(27):e20868; doi: 10.1097/MD.0000000000020868
52.
BlachaC, SchmidMM, GahrM, et al.Self-inflicted testicular amputation in first lysergic acid diethylamide use. J Addict Med, 2013; 7(1):83–84; doi: 10.1097/ADM.0b013e318279737b
53.
MallesonN. Acute adverse reactions to LSD in clinical and experimental use in the United Kingdom. Br J Psychiatry, 1971; 118(543):229–230; doi: 10.1192/bjp.118.543.229
54.
CohenS. Lysergic acid diethylamide: Side effects and complications. J Nerv Ment Dis, 1960; 130:30–40; doi: 10.1097/00005053-196001000-00005
55.
StoneAL, O’BrienMS, De La TorreA, et al.Who is becoming hallucinogen dependent soon after hallucinogen use starts? Drug Alcohol Depend, 2007; 87(2–3):153–163; doi: 10.1016/j.drugalcdep.2006.08.008
56.
BarnettBS, AnandA, WeleffJ, et al.Who keeps using lysergic acid diethylamide? correlates of past-year use in people who initiated use at least five years ago. Psychedelic Medicine, 2025; doi: 10.1177/28314425251367321
57.
BoehnkeKF, CoxK, WestonC, et al.Slouching towards engagement: Interactions between people using psychedelics naturalistically and their healthcare providers. Front Psychiatry, 2023; 14:1224551; doi: 10.3389/fpsyt.2023.1224551
VinaSM. Minorities’ diminished psychedelic returns: Income and educations impact on whites, blacks, hispanics, and asians. J Racial Ethn Health Disparities, 2025; 12(3):1937–1950; doi: 10.1007/s40615-024-02023-y
60.
JonesG, LoweMX, NayakS, et al.Examining differences in the effects and contexts of naturalistic psilocybin use for White participants vs. Participants of Color: A longitudinal online survey study. J Affect Disord, 2025; 370:54–61; doi: 10.1016/j.jad.2024.10.058
61.
MichaelsTI, PurdonJ, CollinsA, et al.Inclusion of people of color in psychedelic-assisted psychotherapy: A review of the literature. BMC Psychiatry, 2018; 18(1):245; doi: 10.1186/s12888-018-1824-6
62.
SchwabishJ, HarveyD, LangnessM, et al.Do No Harm Guide: Collecting, Analyzing, and Reporting Gender and Sexual Orientation Data. 2023.
63.
StreedCG, GrassoC, ReisnerSL, et al.Sexual Orientation and Gender Identity Data Collection: Clinical and Public Health Importance. Am J Public Health, 2020; 110(7):991–993; doi: 10.2105/AJPH.2020.305722
64.
HarrisonL, MartinS, EnevT, et al.Comparing Drug Testing and Self-Report Of Drug Use Among Youths And Young Adults in the General Population. 2007.
65.
BellowsZ, KimC, BaiY, et al.Disparities in self-reported mental health, physical health, and substance use across sexual orientations in Canada. PLoS One, 2025; 20(3):e0305019; doi: 10.1371/journal.pone.0305019
66.
SchulerMS, RiceCE, Evans-PolceRJ, et al.Disparities in substance use behaviors and disorders among adult sexual minorities by age, gender, and sexual identity. Drug Alcohol Depend, 2018; 189:139–146; doi: 10.1016/j.drugalcdep.2018.05.008
67.
NewcombME, BirkettM, CorlissHL, et al.Sexual orientation, gender, and racial differences in illicit drug use in a sample of US high school students. Am J Public Health, 2014; 104(2):304–310; doi: 10.2105/AJPH.2013.301702
68.
Substance Abuse and Mental Health Services Administration. 2019 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions. Rockville, MD; 2020.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
